Endo Pharma: Steady Growth, Challenges Create Attractive Price
Ron Sommer submits:
We first wrote about Endo Pharmaceuticals (ENDP) in a blog post on March 22, 2009. We recommend Endo then and we reiterate that recommendation now.
“Endo Pharmaceuticals Holdings Inc., is a specialty pharmaceutical company in pain management. The Company is engaged in the research, development, sales and marketing of branded and generic pharmaceutical products primarily to treat and manage pain. Its portfolio of branded products includes Lidoderm, Opana ER, Percocet, and Frova. It concentrates on generics that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. During the year ended December 31, 2008, the branded products and non-branded generic portfolio comprised approximately 93% and 7%, respectively, of the Company’s net sales. It markets its branded pharmaceutical products to prescribing physicians in pain management, neurology, surgery, anesthesiology, oncology and primary care. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus Pharmaceuticals, Inc.”
Investing, Long Term Investment, stock market | admin March 2, 2010
RSS feed for comments on this post.
